Several exciting new scientific advances have been made in the past decade toward both understanding the causes of and finding a cure for Parkinson's disease. Heartened by an acceleration in research findings in the past several years, the government has recently called for an infusion of funds from both the National Institutes of Health and private foundations into this burgeoning area of biomedical research. Most currently available conventional treatments for the disease only temporarily delay symptom presentation while doing nothing to halt disease progression. However, the rapidly accelerating pace of research in this field has left researchers hopeful that Parkinson's will be the first major age-related neurodegenerative disease for which we have a viable cure. In this article, advances in various areas of Parkinson's disease research are reviewed.
neurons normally make connections to a part of the midbrain called the striatum (ST). The nigrostriatal connection is part of a larger system of neuronal interconnections that help convert abstract thoughts of movement into voluntary action (Fig. 1) . The release of dopamine by the SN neurons into the striatum normally acts to modulate release of the neurotransmitter γ-aminobutyric acid (GABA) from the striatum. GABA release from the striatum results in inhibition of motor movement. Inhibition of GABA release by dopamine normally is balanced by release of the excitatory neurotransmitter acetylcholine from the motor cortex into the striatum, which acts to stimulate striatal GABA release. Therefore, loss of dopaminergic modulation of GABA release results in muscle rigidity, resting tremor, and gait and balance disturbances. The cause of dopaminergic cell loss in PD is still a mystery to researchers; however, accelerated research discoveries in the past decade have yielded some tantalizing clues that may help halt the progression, restore function, or even prevent the disease.
Unfortunately, most current therapies for PD, while often drastically halting or suppressing the symptoms at early stages in the disease, do nothing to prevent disease progression. The most common treatment for the disease is oral administration of the dopamine precursor L-3,4-dihydroxyphenylalanine (L-DOPA). L-DOPA acts to up-regulate the production of dopamine in the remaining cells in the SN, but does nothing to prevent the eventual death of these cells (3) . As more and more of the cells are lost, increased doses of the drug must be administered, which can result in side effects that might be as distressing to the patients as the disease itself. These include dyskinesia (involuntary motor movements), psychoses, and fluctuations in motor control. As a result of continued cell loss, the drug eventually loses its eff icacy. The ultimate goal in the PD research field is the ability to diagnose the condition at an early stage and to prevent subsequent cell loss from occurring in susceptible individuals.
What Genetic Studies Have Told Us
Like AD, PD does not appear to be a primarily genetic disorder but rather to arise from other causes (such as exposure to environmental toxins, head trauma, viruses, etc.), perhaps coupled with genetic susceptibility (4, 5) . However, much is likely to be gleaned from understanding the molecular pathways that are disrupted in rare familial cases of PD, as these are likely to be the same pathways affected in the more common sporadic forms of the disorder (6) . For example, although mutations in the gene for the presynaptic protein alpha synuclein are present only in a few PD pedigrees, the discovery of this rare autosomal recessive gene mutation led to the realization that aggregates of the protein are a major component of intraneuronal occlusions called Lewy bodies, a pathological hallmark associated with sporadic PD (7) (8) (9) (10) (11) (12) . Aggregation of alpha synuclein and other proteins within these Lewy bodies may play a role in the ensuing cell death. Aberrant protein aggregation is indeed emerging as a common feature of many different neurodegenerative diseases, including AD, Huntington's disease, spinocellular ataxias, and amyotrophic lateral sclerosis (ALS) (13) (14) (15) . Mutations in the so-called parkin gene were discovered in another subset of families with a rare juvenile form of PD, and subsequent studies identified this gene as an E3 ubiquitin protein ligase, an important component of the ubiquitin-proteosome protein degradation pathway. This finding has further fueled the notion that the lack of appropriate disposal of proteins may lead to their aggregation and contribute to disease pathology (16, 17) . In yet another early-onset PD pedigree, a missense mutation was reported in the gene encoding ubiquitin carboxyl-terminal hydrolase L1 (UCH-L1), another enzyme involved in the ubiquitin-proteosome protein degradation pathway (18) . Proteosome function itself recently has been reported to be impaired in the SN of patients with sporadic forms of PD (19) . Polymorphisms on other loci on chromosomes 1p, 2p, and 4p have been reported in other rare inherited forms of PD, but the corresponding genes have yet to be identified (20) (21) (22) .
The identification of inherited gene mutations resulting in PD phenotypes has spurred researchers into attempting to create genetic models of the disease via expression of the corresponding genes in either cultured cells or whole animals. The hope is that expression of these genes will result in models that mimic at least some aspects of the disease. For example, transgenic Drosophila and mouse models that overexpress either the wild-type or mutant forms of the alpha synuclein gene recently have been created (23) (24) (25) (26) . Alpha synuclein transgenic flies display pathological changes similar to those observed in the PD brain, including the selective age-dependent loss of midbrain dopaminergic neurons and the development of intranuclear inclusions resembling Lewy bodies. The flies also display an agerelated loss in locomotor function, although it is not known whether this can specifically be attributed to dopaminergic cell loss or whether dopamine agonists reverse this behavioral phenotype. Mice that express wild-type alpha synuclein in neurons display age-related Lewy body-like formation in the SN, cortex, and hippocampus. However, some of these occlusions appear to be nuclear rather than cytoplasmic and not to be of the normal fibrillary type observed in autopsied brains from PD patients (24) . Although there is no actual loss of midbrain dopaminergic neurons by 1 year of age in the alpha synuclein transgenic mice, there is a slight reduction in the number of striatal dopamine terminals as measured by immunocytochemistry performed with antibodies to tyrosine hydroxylase (TH). In addition, a drop in TH activity was observed in the highest-expression line (the neurons of which express alpha synuclein in the cortex at a level of 80% compared to the corresponding neurons in the normal human brain), suggesting an initiation of the disease. This line also displayed impaired motor ability as measured by the rotorod test, although as with the transgenic flies, it was not determined whether this could be reversed with dopamine replacement therapy (23, 24) . Even if these animals do not completely recapitulate all of the PD pathology, transgenic animal models that express genes mutated in rare familial forms of PD conceivably could be important tools for understanding more about disease symptomology and could aid in diagnosing the condition (27) . They would also be useful for testing the efficacy of various pharmacological treatments (as well as safe and effective gene therapies) before moving these therapies into clinical trials in humans. Finally, such model systems may also assist in the identification of novel therapeutic targets for the disease. Suppressor mutant screens of alpha synuclein flies, for instance, could be used to identify candidate protective gene products.
Although most cases of PD don't appear to be primarily genetic in nature, there still might exist genetic susceptibilities that might render an individual more prone to manifesting the disease in the presence of certain environmental factors. Cardiovascular disease is an illustration of another age-related disorder that appears to result from a combination of both genetic risk and environmental influences. Possible methods for identifying "risk factor" genes include genetic comparison of those affected with the disease with unaffected siblings (sib pair analysis). This would allow the identification of candidate genes involved in susceptibility to the disease. Past twin analysis studies in which disease frequency was compared between cohorts of identical versus fraternal twins found no significant difference between the two, suggesting no underlying genetic cause for sporadic PD (28, 29) . However, recent reanalysis of the data suggests that low penetrance could explain these results. Furthermore, subsequent positron emission tomography (PET) analysis suggests that the asymptomatic identical twin sibs of affected patients displayed presymptomatic signs of the disease (30) . In PET, fluorodopa is administered intravenously and is allowed to be converted into dopamine within the nigrostriatal system, where it can then be noninvasively imaged at high resolution to assess dopamine synthesis capacity in this brain region as a measure of neuronal cell function. Although these results suggest that there might be some genetic involvement in PD, shared environmental influences cannot be ruled out (31) .
The analysis of complex genetic traits at a population level is currently being revolutionized through the large influx of information from the human genome project and the use of novel technologies such as gene microarray and proteomic analyses. In these types of analyses, patterns of expression of tens of thousands of genes or proteins can be assessed simultaneously to look for a "fingerprint" of gene or protein expression associated with the disease (32) (33) (34) . This fingerprint can then be used both as a diagnostic tool and to identify novel genes and proteins that are differentially expressed during various stages of the disease process. Such genes and proteins may represent novel targets for therapy or biomarkers for the disease.
What Studies of Environmental Interactions Have
Told Us PD appears to be most prevalent in industrialized countries. In addition, people moving from nonindustrial countries with low disease incidence to industrial countries with higher disease incidence show an increased occurrence of the disease (4). This suggests that industrial toxins might play a role in PD.
On the basis of these obser vations, numerous epidemiological studies have been performed to identify environmental factors that might predispose individuals for the disease (35) (36) (37) (38) (39) (40) (41) . The most common of these types of studies involve comparisons between people with and without PD (case-control studies). Results from several epidemiological studies, for example, have suggested that populations that drink well water have a higher incidence of sporadic forms of the disease (42) . This observation gives credence to the notion that exposure to environmental industrial toxins such as certain herbicides and pesticides may increase the risk for PD (43) . Identification of such potential toxins allows scientists to follow people who have experienced exposure to a particular putative toxin to see if they develop symptoms of the disease (long-term studies). These symptoms can be correlated with gene/protein profiles to assess the interplay between toxin exposure and genetic susceptibility. The profiles may also aid in identifying preclinical characteristics of disease. In PD, as is the case with many other multifactorial diseases, interpretation of these experiments may be difficult because of the complex nature of the illness. In order to expedite such work, large pedigrees with familial PD need to be identified and carefully characterized for use in testing the relation between environment and genetic predisposition and to assess the efficacy of preventative treatments. In addition, the role of age, gender (PD is reported to be higher in men than women), race (PD is reported to be higher in Caucasian than in other racial populations), and geographic distribution needs to be assessed (4) . These analyses would help to address issues such as whether noted epidemiological trends are due to actual disease incidence or rather to the underreporting of PD as the cause of death in minority or other populations. Studies in animal models of PD appear to support the noted epidemiological male-female differences in PD susceptibility in humans. This raises the possibility of a protective role for female hormones such as estrogen (44) (45) (46) .
What Basic Scientific Research Has Told Us
Advances over the past couple of decades in the basic neurosciences have increased our understanding of the fundamental mechanisms involved in neuronal cell death, which may help us to know more about the dopaminergic cell loss that occurs in PD. Both postmortem data from human PD patients and data from research using various cellular and animal models of the disease strongly suggest that mitochondrial dysfunction is a major cause of neuronal cell death (47) (48) (49) . Mitochondria are the power plants of the cell. Compromise of their function results in the cell's inability to produce adequate energy supplies in the form of adenosine 5′-triphosphate (ATP) to sustain itself. ATP is synthesized via an intricate series of electron transfer reactions involving five sequential mitochondrial protein complexes (I through V) (Fig. 2 ) (for review, see http://sageke. sciencemag.org/cgi/content/full/sageke;2001/1/oa5). Mitochondria also generate reactive oxygen species (ROS), which are toxic byproducts generated during conversion of high-ener- gy oxygen to low-energy water as fuel for ATP production. ROS production may also contribute to cellular degeneration.
The link between neuronal cell demise in PD and mitochondrial dysfunction was originally discovered as a consequence of the manufacturing of an illegal drug gone awry. In 1982, drug addicts in the San Francisco Bay area, while attempting to make an illegal heroin analog, overcooked the concoction, which resulted in the formation of a compound known as 1-methyl-4-phenyl 1,2,3,6-tetrahydropyridine (MPTP). Injection of MPTP resulted in acute "end stage" Parkinsonism in these individuals, due to the rapid loss of the same set of neurons that are destroyed in PD (50) . Administration of MPTP to experimental animals results in similar effects (51, 52) . Animal studies have demonstrated that MPTP acts as an inhibitor of mitochondrial complex I, one of the principle entry points for electrons into the electron transport chain. Interestingly, the activity of this enzyme complex is decreased selectively in the SN of PD patients (Fig. 3) (53-55) . In addition, when rodents are treated with chronic low doses of rotenone, a mitochondrial complex I inhibitor that was once used both as an insecticide and as a means to cull fish populations, they develop PD-like pathology, including progressive nigrostriatal degeneration, formation of Lewy body-like occlusions, and motor deficits. These pathologies have been shown to be reversed upon treatment with a dopamine receptor agonist (56) .
Aberrant mitochondrial function that results in cell death can take forms other than energetic failure or production of ROS, including dysregulation of the control of intracellular calcium levels or induction of a form of genetically regulated cell suicide known as apoptosis (57) . Indices of all of these types of damage are found to various degrees in the brains of PD patients and in various animal and cellular models of the disease [for examples, see (2, 5, 25-27, 49, 55, 58-62) ]. These various mechanisms of cell death can act singly or in concert to elicit the cell's demise. In our laboratory, for example, we recently demonstrated that reduction of the antioxidant glutathione (GSH) in dopamine-containing cells in vitro results in the selective inhibition of mitochondrial complex I activity, suggesting there is a causative link between the two (63) . GSH depletion is the earliest reported detectable biomarker for PD, and the degree of loss closely correlates with the severity of the disease (64) (65) (66) . Loss of GSH coupled with the presence of dopamine, which can be oxidized to form toxic oxidant metabolites, and a high iron content in this brain region, which can exacerbate this oxidation process, may lead to increased ROS in dopaminergic SN neurons, making them more vulnerable to degeneration (67) (68) (69) . L-DOPA treatment itself has been proposed to result in the generation of toxic oxidative species ("oxidative stress") that may contribute to cell loss, although this hypothesis is controversial (70) (71) (72) . Oxidative stress and subsequent damage to cellular proteins may secondarily lead to protein aggregation, which can contribute to the pathology of PD. In addition, recent unpublished results from our laboratory suggest that GSH depletion can directly affect the ubiquitin pathway by allowing increased thiol oxidation of the E1 and E2 ligases, which are crucial enzymes involved in the transfer of ubiquitin to the appropriate protein. This in turn could affect the ability of proteins to be properly degraded and lead to aggregation.
From Scientific Findings to Pharmacological Intervention
Because mitochondrial impairment appears to play a pivotal role in the demise of dopaminergic SN neurons in PD, nutritional agents that act to enhance bioenergetic function may be therapeutic (73) . Oral administration of CoQ, a cofactor involved in the transport of electrons between complexes I and II and a potential antioxidant, and nicotinamide adenine dinucleotide (NADH), a substrate for complex I, have both been reported to prevent cell death in various animal models of PD and to improve symptoms in PD patients themselves (74) (75) (76) (77) (78) . CoQ subsequently was found to be ineffective in a short clinical trial in humans, although there was a trend toward increased mitochondrial complex I activity (79) . On the basis of these results, the period of the trial has been extended. NADH given either intravenously or orally has been reported to improve disability in PD patients. Creatine, a substrate for creatine kinase, which is involved in ATP production, has been reported to be protective in the MPTP model of PD (80) . These results taken in total suggest that bioenergetic supplementation may hold promise as a therapeutic for PD.
ROS production has emerged as another important contributing factor in PD-related neuronal cell death (58, 62, (81) (82) (83) . On the basis of earlier epidemiological reports, a large clinical trial called DATATOP was conducted in the early 1990s to assess the efficacy of oral administration of the antioxidant vitamin E with respect to PD symptoms. Although vitamin E was found to be ineffectual in this study, the chemical deprenyl was found to delay the need for L-DOPA therapy and provided at least some temporary symptomatic relief to patients (84, 85) . Deprenyl is an inhibitor of monoamine oxidase B (MAO-B), which catalyzes the oxidation of dopamine. It is important to note that the levels of vitamin E used in the DATATOP study were less than those found to be successful in a previous, smaller clinical study, so dosage may be an issue (86) . Another small clinical trial in which GSH was administered intravenously to PD patients over a 1-month period revealed that this treatment showed some efficacy in terms of improved motor ability (87) . GSH does not easily cross the blood-brain barrier (BBB), which may limit its usefulness as a therapy on its own. However, alternatives to GSH therapy have been suggested for testing in clinical trials, including the GSH precursor N-acetylcysteine or the GSH substitute lipoic acid, or esterized forms of the compound that can more easily cross the BBB (88) . In addition, extremely potent antioxidant enzyme mimetics called EUKs have been developed recently and were shown to prevent MPTP-induced cell death in PD models (89) . These compounds have the added important benefit of being able to cross the BBB easily. They also have been shown to increase life-span in Caenorhabditis elegans, presumably through reduction of age-related oxidative stress (90) .
Although initially controversial, evidence is building that apoptosis may play an important role in the neuronal cell death associated with PD (91, 92) . Induction of apoptosis in PD as in other neuronal cell death scenarios probably involves the activation of a cascade of cysteine proteases called caspases. Two members of this cascade, upstream caspase 8 and downstream caspase 3, have been reported to be present in dying SN neurons in the brains of autopsied tissue from PD patients (93) . Unpublished data from our own laboratory suggest that mice that express the general caspase inhibitor protein baculoviral p35 in neurons are more resistant to MPTP toxicity, and Beal and col-leagues have demonstrated that mice expressing a dominantnegative form of caspase 1 also display decreased MPTP-induced SN cell death (94) . These observations suggest that pharmacological caspase inhibitors may constitute another possible avenue of therapy for PD. Such compounds are already being tested clinically for their efficacy in other neurological conditions in which apoptosis has been suggested to play a role (for example, stroke) (95) .
How various interrelated mechanisms of cell death such as mitochondrial dysfunction, oxidative stress, apoptosis, and protein aggregation result in the selective death of dopaminergic SN neurons in PD is still not completely understood. However, by understanding the basic molecular processes involved in neuron loss, we might be able to delay or even halt dopaminergic SN cell death through a combination of therapeutic approaches (for example, bioenergetic supplements, antioxidants, metal chelators, caspase inhibitors, etc.) (96) . In addition, with high-throughput drug screening assays that measure the functions of molecular players in the process of selective cell death, it is possible to test the effects of large numbers of small molecules on these molecular targets for drug therapy. This, of course, requires adequate cellular models of the disease, but could include, for instance, assessment of the ability of drugs to inhibit toxin-induced apoptosis or alpha synuclein aggregation in dopaminergic neurons in culture.
Possible Roads to Therapeutics
Prolonged exposure of neurons to the excitatory neurotransmitter glutamate can result in excitotoxic cell death. This is especially the case for vulnerable cells with compromised energy metabolism. Dopaminergic neurons of the SN express glutamate receptors, and these cells degenerate when exposed to excitoxins. In vivo treatment with various excitotoxin agonists has been demonstrated to attenuate MPTP-induced cell death, especially with agonists specific for the NMDA-type glutamate receptor [for review, see (97) (98) (99) ]. Attentuation of glutamate transmission by other means, including both pharmacological and surgical interventions (see below), also appears to attenuate the symptoms of PD. It is not clear whether removing excess glutamate input into the nigrostriatal system, however, really protects or only delays dopaminergic cell death.
Inflammation, initiated most likely in response to nerve cell damage, also appears to be involved in PD pathogenesis. Microglial activation has been demonstrated both in the MPTP animal model and in PD patients [for example, see (100-105)]. It has been suggested that microglia elicit their toxic effects by production of nitric oxide (NO) through induction of the enzyme nitric oxide synthase (NOS) in these cells. NO can in turn react with superoxide to form peroxynitrite, which can elicit nitration of tyrosine residues on proteins such as TH, the rate-limiting enzyme in dopamine synthesis. Nitration of tyrosine residues can thus affect the function of these target proteins. Evidence suggesting the presence of nitrotyrosine has been observed both in PD animal models and in patients (106) (107) (108) . NOS inhibitors might be another possible therapy for the disease and indeed have been reported to be effective in attenuating disease progression in various animal models (109) . Neuroimmunophilins have also been reported to elicit both protective and restorative effects, although interestingly not due to their immunosuppressive actions. Rather, these effects appear to result from inhibition of calcineurin, which can induce NOS activity (110) (111) (112) . Neuronally derived NOS may be another important component of cell death in PD, as NOS inhibitors also appear to be protective in animal models (113, 114) .
Delivery of protective neurotrophic growth factors to dopaminergic SN neurons and their terminals in the striatum is another hotly pursued line of research in the PD field. This approach was previously hindered by the lack of effective methods of delivery for clinical usage (115) . Most neurotrophic agents are large molecules that don't easily cross the BBB. Microinjection has worked well in animal models but less well in patients. Recently, Kordower and colleagues demonstrated that delivery of glial-derived growth factor (GDNF), a neurotrophic factor relatively selective for dopaminergic neurons, using lentivirus as a vector for its expression, resulted in sustained expression of the protein over a several-month period and functional recovery from MPTP-mediated Parkinsonism in the majority of rhesus monkeys treated with the agent (116) . The degree of recovery correlated well with prevention of loss of dopaminergic terminals in the striatum. This produced much excitement in the Parkinson's research community. However, several parameters still need to be carefully assessed before human trials can be contemplated. For example, how safe for human use is lentivirus, an HIV-related virus? Concern was raised over the fact that a small number of the injected animals died after treatment with the virus. Is the virus capable of expressing the transgene for years as opposed to only months? Sustained expression may be necessary to maintain the function of the dopamine SN neurons over the life-span of the affected individual. Also, not all monkeys that displayed effective delivery and expression of the transgene showed recovery-what needs to be done to optimize the procedure?
Toxic models such as MPTP or rotenone administration, along with novel genetic models of PD, now allow scientists to examine the progression of PD as it occurs. This provides researchers with the opportunity to identify which molecular processes are important at each stage of the disease and to pinpoint places at which therapeutic interventions can be administered. Such model systems also allow scientists to assess the types of compensatory changes that occur in the cells or circuitry as a result of the disease. For example, researchers can determine whether loss of dopamine in the SN neurons leads to chronic alterations in related synapses, neurons, and circuits, such as molecular changes in the concentrations of neurotransmitter receptors or signal transduction molecules that can affect the presentation of disease symptoms. If these physiological changes help to delay the course of the disease, it may be possible to emulate these changes using pharmacological agents. By understanding dopaminergic SN neuronal function and how it fits into the larger neural circuitry of the brain, it also might be possible to restore the lost function via protein (for example, neurotrophin) or dopaminergic cell replacement. Understanding the complexities of the affected circuitry has already yielded information leading to surgical manipulations that control some of the symptoms of PD. An example is neuronal ablation of pathways from other brain regions that send inhibitory signals to the striatum, such as from the globus pallidus. A depiction of this so-called "pallidotomy" can be seen at http://medweb.bham. ac.uk/http/depts/clin_neuro/teaching/tutorials/parkinsons/surgery/parkinsons-surgery.html or www.pallidotomy.com/parkinson_s_disease.html). Another procedure developed more recently is deep brain stimulation of the subthalamus nuclei (117) (118) (119) . In this procedure, a device is implanted into the brain that allows chronic electrical stimulation of neurons in an attempt to restore normal neuronal circuitry; this relieves many of the symptoms of the disease and the affects appear to be long-lasting. However, the problem with current surgical interventions is that, in general, they only deal with the symptoms of the disease and not the ongoing progressive cell loss.
Cell Replacement Therapy: How Feasible Is It?
Another exciting area of current PD research involves the replacement via transplantation of the dopaminergic SN neurons lost in the disease. A plus for the use of cell transplantation therapy in PD is that the nigrostriatal system is fairly easily accessible and well-defined structurally. Transplantation is usually done directly into the striatum, so that the transplanted dopaminergic cells can easily make connections with the striatal neurons (120) . Studies in this area of research suggest that transplantation works best when the recipient is young (that is, during fetal development), although grafted cells are capable of surviving and making functional connections even in the adult brain. Numerous studies in various animal models of PD have suggested that transplanted cells can undergo normal dopamine synthesis, turnover, and release and that their presence can act to attenuate behavioral symptoms (120) . However, it is important to note in this context that the vast majority of PD patients are over the age of 65, and the older the host, the less efficient the transplant is likely to be. In addition, in humans we know little about how to regulate cell growth and function once cells are transplanted into the brain. On the basis of some promising preliminary results from animal studies, surgeries were performed on several PD patients involving the implantation of their own dopamine-producing carotid bodies into the striatum before it was realized that this method of dopaminergic cell delivery was ineffective because of poor graft survival (121) . There also have been reports of several scattered clinical cases touting the efficacy of fetal tissue grafts as a therapeutic for the disease; however, a recent large double-blind fetal transplant study produced disappointing results with less-than-desired levels of benefits and side effects (122) . These results preclude for the moment the widespread usage of fetal transplantation in PD patients until more clinical trials are completed [for review, see (123) (124) (125) ]. The published study was done without immunosuppressants, although PET scan analysis suggests that the grafts survived even without the use of these agents. Other important factors to be assessed in terms of fetal transplant include methods and timing of tissue storage before transplant, amount of tissue to be transplanted, and which growth factors allow the best maintenance of the cells in vivo. Such parameters may have major impacts on the number of neurons that ultimately survive the grafting procedure. It is estimated that approximately 80,000 functional dopaminergic neurons, or roughly one-fifth of the normal SN complement of neurons, are needed for the treatment to succeed (120) . There are many moral and social issues connected with the use of fetal tissue, even though thus far these types of cells appear to work best in grafting experiments. And only a limited amount of such tissue is available.
Another source of tissue for transplantation is embryonic stem cells. Stem cells are undifferentiated cells that can renew themselves by cell division and can give rise to many types of more specialized cells (126) . Stem cells from the embryo are pluripotent; that is, they differentiate into all known cell types. In contrast, adult stem cells may give rise only to certain defined lineages. The dream among researchers is that easily accessible cells might someday be used to treat diseases such as PD. Indeed, cells from the bone marrow recently were shown to be capable of migrating into the brain and becoming neuronal-like cells (127) . The ability to use cells such as those from the bone marrow has two benefits. One is that it would eliminate the ethical concerns associated with the use of fetal tissue. The second is the eradication of immune rejection, as the patient's own cells could be used. Multipotent stem cells potentially can be an unlimited source of transplantation materials. First, however, they must be expanded into sufficient numbers for transplantation (as they are rare) and predifferentiated in vitro toward a dopaminergic cell fate. What controls the proliferation and differentiation of stem cells is still poorly understood. It is particularly important to ascertain whether they retain their pluripotent capacity after transplantation and differentiate into fully functional dopaminergic neurons. It is also unknown whether regionalspecific glial support cells will be required in order to get proper dopaminergic cell induction and function in vivo.
Many exciting new avenues of potential PD therapy have been opened up thanks to major advances in various research areas over the past several years (F. 4). With the influx of new combined government and foundation spending to bolster research efforts toward finding its cause and treatment, hopes are high that PD will be the first major neurodegenerative disease for which we find a cure.
